Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 10 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Long-term outcome of patients with Crohn's disease who respond to azathioprine

The latest issue of Clinical Gastroenterology & Hepatology investigates long-term outcome of patients with Crohn's disease who respond to azathioprine.

News image

Little is known about the long-term outcomes of patients with Crohn's disease who have a complete response to therapy with azathioprine.

Dr Marine Camus from France evaluated the long-term effects of azathioprine in responders.

The team collected data from the MICISTA registry on consecutive Crohn's disease patients treated with azathioprine from 1987 to 1999 who responded to therapy, and followed up until 2011.

Data were compared with those from 440 matched patients with Crohn's disease who did not receive immunosuppressants during the same inclusion period.

The doctors found that the cumulative rate of sustained remission 10 years after treatment with azathioprine was 38%.

Among patients exposed to azathioprine during a prospective follow-up period, the percentage of patient-years with active disease was 18%.

The researchers assesed that compared with the control group, at baseline, responders were more often active smokers with significantly more extensive disease, perianal lesions, and extradigestive manifestations.

Sustained remission 10 years after treatment with azathioprine was 38%
Clinical Gastroenterology & Hepatology

During follow-up evaluation, responders had a significantly reduced risk of intestinal surgery and perianal surgery.

The team of doctors noted that a significantly higher percentage of responders developed cancers, including nonmelanoma skin cancers, compared with controls.

Survival rates after 20 years were 93% of responders vs 98% of controls.

Dr Marine's team concluded, "Based on a study at a single center, patients with Crohn's disease who responded to azathioprine had a smaller proportion of patient-years with active disease, and were less likely to be hospitalized or undergo intestinal surgery, than patients with Crohn's disease who did not receive immunosuppressants."

"These benefits, however, could be offset by an increased risk of malignancies."

Clin Gastroenterol Hepatol 2013: 12(4): 389-94
28 March 2013

Go to top of page Email this page Email this page to a colleague

 09 December 2016 
Use of GI alarm features for colorectal cancer diagnosis
 09 December 2016 
Emergency department use by IBD patients
 09 December 2016 
PPI regimens for upper GI bleeds
 08 December 2016 
Preterm birth in women with IBD
 08 December 2016 
Precision medicine in IBD
 08 December 2016 
Intestinal tuberculosis vs Crohn's disease
 07 December 2016 
Iron deficiency in ulcerative colitis
 07 December 2016 
IBD source of information and patient education
 07 December 2016 
End-of-rotation resident transition and in-hospital mortality
 06 December 2016 
Anti-TNF therapy for IBD
 06 December 2016 
Crohn's disease and thyroid cancer risk
 06 December 2016 
IBD Disability Index in restorative proctocolectomy
 05 December 2016 
Reducing hospitalization in IBD
 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Treating Zenker's diverticulum
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Quality assurance standards for colonoscopy
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 21 November 2016 
Financial incentives and colorectal cancer screening
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Liver-related specialty care in patients with Hep C
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Contraceptives and ulcerative colitis
 15 November 2016 
Physician perspectives on Hep C management
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us